BioVie Investor Relations Material
Latest events
AGM 2025
BioVie
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioVie Inc
Access all reports
BioVie Inc. is a clinical stage biopharmaceutical company based in the United States, focusing on the discovery, development, and commercialization of innovative drugs for the treatment of chronic debilitating conditions. The company's pipeline includes key drug candidates like BIV201 for the treatment of ascites due to chronic liver cirrhosis as well as NE3107, aimed at treating neurodegenerative disorders. NE3107 is in clinical trial for mild to moderate Alzheimer's disease and Parkinson's disease. It is headquartered in Carson City, Nevada, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
BIVI
Country
🇺🇸 United States